News
27.6.22

Scientific Publication in the International Journal of Molecular Sciences

We are happy to announce that the manuscript entitled "A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts" was accepted for publication in the International Journal of Molecular Sciences.

ABSTRACT - Wound healing pathologies are an increasing problem in ageing societies. Chronic, non-healing wounds, which cause high morbidity and severely reduce the quality of life of affected individuals, are frequently observed in aged individuals and people suffering from diseases affected by the Western lifestyle, such as diabetes. Causal treatments that support proper wound healing are still scarce. Here, we performed expression proteomics to study the effects of the small molecule TOP-N53 on primary human skin fibroblasts and keratinocytes. TOP-N53 is a dual-acting nitric oxide donor and phosphodiesterase-5 inhibitor increasing cGMP levels to support proper wound healing. In contrast to keratinocytes, which did not exhibit global proteome alterations, TOP-N53 had profound effects on the proteome of skin fibroblasts. In fibroblasts, TOP-N53 activated the cytoprotective, lysosomal degradation pathway autophagy and induced the expression of the selective autophagy receptor p62/SQSTM1. Thus, activation of autophagy might in part be responsible for beneficial effects of TOP-N53.

Download DocumentDokument herunterladenhttps://www.mdpi.com/1422-0067/23/12/6860https://www.mdpi.com/1422-0067/23/12/6860
6.7.21
Press Release

TOPADUR Pharma AG announces completion of TOP-N53 First-in-Man Study

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.

Read more
20.5.20
News

Scientific Publication in the Journal of Investigative Dermatology

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Promotes Wound Healing in Normal and Diabetic Mice.

Read more
8.10.20
News

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.

Read more